Kepler Capital analyst David Evans maintained a Buy rating on Novartis AG (NOVN – Research Report) on March 13 and set a price target of ...

American football’s elite National Football League (NFL) has brought in US medicine company Novartis as the property's ...

Crizanlizumab (Adakveo) failed to outperform placebo in patients with sickle cell disease, the phase III STAND trial showed.

A cohort study of over 40,000 patients suggests that levels should be monitored for at least three months — longer than commonly practiced ...

Novartis has teamed up with the NFL in a multi-year partnership, marking the first such collaboration between the football ...

The NFL have signed its first-ever pharmaceutical partner in a multi-year deal with Novartis to focus on the NFL’s health ...

The National Football League has signed its first-ever pharmaceutical partner in a multi-year deal with Switzerland-based ...

Legend Biotech is building a new $150 million manufacturing plant, with its partner Johnson & Johnson, with the goal of ...

The NFL has inked a multi-year deal with pharmaceutical giant Novartis, marking its first such partnership. This ...

The RNA inhibitor reduces levels of oxidized phospholipids, which are presumed to promote atherosclerosis, by more than 93%.